Rocklatan vs Latanoprost Post-DSLT

Part of paid clinical trials in Beaumont, Texas.

Sponsor: Eye Centers of Southeast Texas
Study ID: NCT07465913
Phase: PHASE4
Status: Recruiting

Apply to this trial

Conditions

Glaucoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Rocklatan 0.02%-0.005% Ophthalmic Solution — DRUG
netarsudil and latanoprost 0.02%/0.005%
Latanoprost 0.005% Ophthalmic Solution — DRUG
Latanoprost 0.005%

Study Details

This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.